Revelation Biosciences Launches Phase 1 Gemini Clinical Trial

Revelation Biosciences, a NASDAQ-listed life sciences firm, has initiated a Phase 1 clinical trial for its proprietary compound Gemini, which is designed to leverage trained immunity for disease prevention and treatment. The study, RVL-HV02, involves administering varying doses of Gemini intravenously to healthy volunteers aged between 18 and 55 in Australia. The company anticipates releasing key findings, encompassing safety, tolerability, and biomarker activity, later this year. These results are expected to guide future development across various medical applications.
Gemini, a TLR4 agonist, is believed to condition the innate immune system to better respond to subsequent stressors, such as ischemia or bacterial infections. It is currently being developed to prevent or mitigate acute kidney injury (AKI) following cardiac surgery and to reduce the risk and severity of post-surgical infections. Preclinical studies have shown that Gemini pretreatment can lessen the severity and duration of AKI and decrease infection rates and severity.
James Rolke, CEO of Revelation, highlighted the growing health concern of AKI, particularly among patients with conditions like diabetes, noting the absence of approved preventive therapies. He also emphasized the need for new treatments to address post-surgical infections and antibiotic resistance. The study's commencement represents a significant step towards developing new therapies for these pressing medical needs.
Gemini's potential applications extend to chronic kidney disease treatment and are based on the concept of trained immunity, which modulates the innate immune system's response to stress. Revelation has conducted several preclinical studies that demonstrate Gemini's therapeutic potential in the targeted conditions.
Revelation Biosciences is dedicated to utilizing Gemini for disease prevention and treatment, with ongoing programs for post-surgical infection prevention, AKI prevention, and chronic kidney disease treatment. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!